Identification of the Rassf3 Gene As a Potential Tumor Suppressor

Total Page:16

File Type:pdf, Size:1020Kb

Identification of the Rassf3 Gene As a Potential Tumor Suppressor Clemson University TigerPrints All Dissertations Dissertations 12-2006 Identification of the Rassf3 Gene as a Potential Tumor Suppressor Responsible for the Resistance to Mammary Tumor Development in MMTV/ neu Transgenic Mice Isabelle Jacquemart Clemson University, [email protected] Follow this and additional works at: https://tigerprints.clemson.edu/all_dissertations Part of the Microbiology Commons Recommended Citation Jacquemart, Isabelle, "Identification of the Rassf3 Gene as a Potential Tumor Suppressor Responsible for the Resistance to Mammary Tumor Development in MMTV/neu Transgenic Mice" (2006). All Dissertations. 26. https://tigerprints.clemson.edu/all_dissertations/26 This Dissertation is brought to you for free and open access by the Dissertations at TigerPrints. It has been accepted for inclusion in All Dissertations by an authorized administrator of TigerPrints. For more information, please contact [email protected]. IDENTIFICATION OF THE Rassf3 GENE AS A POTENTIAL TUMOR SUPPRESSOR RESPONSIBLE FOR THE RESISTANCE TO MAMMARY TUMOR DEVELOPMENT IN MMTV/neu TRANSGENIC MICE A Dissertation Presented to the Graduate School of Clemson University In Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy Microbiology by Isabelle C. Jacquemart December 2006 Accepted by: Dr. Wen Y. Chen, Committee Chair Dr. Charles D. Rice Dr. Lyndon L. Larcom Dr. Lesly Temesvari i ABSTRACT The MMTV/neu transgenic mouse line is a well-documented animal model for studying HER2/neu-related breast cancer. It has been reported that a small percentage, approximately 20%, of the virgin female MMTV/neu mice seems resistant to the development of mammary gland adenoma, despite the overexpression of the neu oncogene. To identify the factors that are responsible for the tumor resistance in these MMTV/neu female transgenic mice, comparative genetic profiling was used to screen the alterations in gene expression in the mammary gland. A novel gene named the RAS Association domain (RalGDS/AF-6) Family 3 (Rassf3), which belongs to a family of RAS effectors and tumor suppressor genes was identified in this study. Data presented in this dissertation show: 1) that the Rassf3 gene is overexpressed in the mammary gland of the tumor-resistant MMTV/neu mice compared to their tumor-susceptible MMTV/neu transgenic littermates or age-matched non-transgenic FVB mice, and 2) that the Rassf3 gene is significantly up-regulated in neu-specific mouse mammary tumors compared to adjacent normal tissues. To further confirm the role of the Rassf3 gene in mammary carcinogenesis, a series of in vitro and in vivo experiments were explored. The results show that overexpression of RASSF3 inhibits cell proliferation in HER2 positive human and mouse breast cancer cell lines. The inhibitory effect of RASSF3 seems to be through induction ii of apoptosis. In addition, co-transfection of the Rassf3 gene with the activated H-RAS gene in SKBR3 human breast cancer cells decreased H-RAS protein level, suggesting that RASSF3 protein can indirectly interact with H-RAS protein. A novel MMTV/Rassf3-neu bi-transgenic mouse line, overexpressing both Rassf3 and neu genes in mammary glands, was also established. The mammary tumor incidence in virgin female bi-transgenic mice was delayed compared to their MMTV/neu+/- littermates. Together, these data suggest that Rassf3, a RAS effector, is a candidate gene that may influence the mammary tumor incidence in virgin female MMTV/neu transgenic mice. iii ACKNOWLEDGEMENTS Several individuals have played a major role in the development of this dissertation. My advisor, Dr. Wen Y. Chen, has been of great assistance and guidance throughout my four years of study at Clemson. His depth of knowledge and experience in the field of Molecular Biology has sparked many conversations and ideas that are shown through my work. I am very grateful for the role he has played in my education. I would also like to recognize the support received from my friends and colleagues, Jang P. Park, John F. Langenheim and Seth Tomblyn at the Molecular Biology Lab of the Oncology Research Institute in Greenville Hospital System. Special thanks go to my friends and colleagues Michele L. Scotti for her encouragement and friendship throughout my program and Alison E. Spring for her support and assistance in the preparation of this dissertation. In addition, I would like to thank Ms. Margaret Nicholson, the Executive Director of the Fulbright Program in Belgium and Dr. Calvin L. Schoulties, the Dean of the College of Agriculture, Forestry and Life Sciences at Clemson University for their sponsor and support throughout my program at Clemson University. Finally, I would like to thank my family. There have been countless conversations of motivation that have kept my morale up and pushed me to complete this work. Their love, understanding and encouragement are what brought me to Clemson and helped me achieved my goals during these four years of study. iv TABLE OF CONTENTS Page TITLE PAGE ......................................................................................................... i ABSTRACT ........................................................................................................... ii ACKNOWLEDGEMENTS ................................................................................... iv LIST OF TABLES ................................................................................................. viii LIST OF FIGURES ............................................................................................... ix ABBREVIATIONS ............................................................................................................. xii CHAPTER 1. INTRODUCTION ................................................................................... 1 1.1. Cancer ........................................................................................ 1 1.2. Oncogenes, Tumor Suppressors and Stability Genes ........................................................................ 3 1.3. Hallmarks of Cancer .................................................................. 6 1.4. Breast Cancer ............................................................................. 10 1.5. HER2/neu Oncogene .................................................................. 23 1.6. RAS Oncogene ........................................................................... 36 1.7. The Use of Transgenic Mouse Technology in Cancer Research ...................................................................... 47 1.8. The Use of Gene Expression Profiling in Cancer Research ...................................................................... 53 2. HYPOTHESIS AND OBJECTIVES....................................................... 57 3. MATERIAL AND METHODS............................................................... 58 3.1. Animal Model ............................................................................ 58 3.2. RNA Isolation ............................................................................ 58 3.3. Microarray Analysis ................................................................... 59 3.4. Reverse Transcription-PCR (RT-PCR) ...................................... 62 3.5. Cloning and Plasmid Construction ............................................ 65 v Table of Contents (Continued) Page 3.6. RASSF3 Protein Production ...................................................... 68 3.7. Custom Antibody Design and Production ................................. 69 3.8. Cell Culture and Reagents ......................................................... 72 3.9. Protein Isolation and Western Blot Analysis ............................. 73 3.10. Transient Transfection ............................................................. 76 3.11. Cell Proliferation MTS/PMS Assay ......................................... 76 3.12. Apoptosis Assay ....................................................................... 77 3.13. Generation and Study of Transgenic Mice .............................. 78 3.14. Mammary Gland Whole Mounts ............................................. 80 3.15. Statistical Analyses .................................................................. 81 4. RESULTS ............................................................................................... 82 4.1. Comparison of the Mammary Gland Morphology of the MMTV/neu Transgenic Mice ....................................... 82 4.2. Identification of Differentially Expressed Genes by cDNA Microarray Analysis ............................................... 84 4.3. Analysis of the Differentially Expressed Candidate Genes ..................................................................... 90 4.4. Functional Studies of the Rassf3 Gene in HER2/neu-initiated Breast Cancer .......................................... 102 4.5. Generation and Analysis of Novel Transgenic Mouse Lines: The MMTV/Rassf3 Transgenic Mice and MMTV/Rassf3-neu Bi-Transgenic Mice ................................................................ 114 5. DISCUSSION ......................................................................................... 125 5.1. HER2/neu Human Breast Cancer and its Mouse Models ..................................................................................... 125 5.2. Identification of the Genes Responsible for the Tumor Resistant Phenotype in MMTV/neu Transgenic Mice by cDNA Microarray Analysis ................................................................................... 129 5.3. Analysis
Recommended publications
  • Searching for Novel Peptide Hormones in the Human Genome Olivier Mirabeau
    Searching for novel peptide hormones in the human genome Olivier Mirabeau To cite this version: Olivier Mirabeau. Searching for novel peptide hormones in the human genome. Life Sciences [q-bio]. Université Montpellier II - Sciences et Techniques du Languedoc, 2008. English. tel-00340710 HAL Id: tel-00340710 https://tel.archives-ouvertes.fr/tel-00340710 Submitted on 21 Nov 2008 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. UNIVERSITE MONTPELLIER II SCIENCES ET TECHNIQUES DU LANGUEDOC THESE pour obtenir le grade de DOCTEUR DE L'UNIVERSITE MONTPELLIER II Discipline : Biologie Informatique Ecole Doctorale : Sciences chimiques et biologiques pour la santé Formation doctorale : Biologie-Santé Recherche de nouvelles hormones peptidiques codées par le génome humain par Olivier Mirabeau présentée et soutenue publiquement le 30 janvier 2008 JURY M. Hubert Vaudry Rapporteur M. Jean-Philippe Vert Rapporteur Mme Nadia Rosenthal Examinatrice M. Jean Martinez Président M. Olivier Gascuel Directeur M. Cornelius Gross Examinateur Résumé Résumé Cette thèse porte sur la découverte de gènes humains non caractérisés codant pour des précurseurs à hormones peptidiques. Les hormones peptidiques (PH) ont un rôle important dans la plupart des processus physiologiques du corps humain.
    [Show full text]
  • The EMILIN/Multimerin Family
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE REVIEW ARTICLE published: 06 Januaryprovided 2012 by Frontiers - Publisher Connector doi: 10.3389/fimmu.2011.00093 The EMILIN/multimerin family Alfonso Colombatti 1,2,3*, Paola Spessotto1, Roberto Doliana1, Maurizio Mongiat 1, Giorgio Maria Bressan4 and Gennaro Esposito2,3 1 Experimental Oncology 2, Centro di Riferimento Oncologico, Istituto di Ricerca e Cura a Carattere Scientifico, Aviano, Italy 2 Department of Biomedical Science and Technology, University of Udine, Udine, Italy 3 Microgravity, Ageing, Training, Immobility Excellence Center, University of Udine, Udine, Italy 4 Department of Histology Microbiology and Medical Biotechnologies, University of Padova, Padova, Italy Edited by: Elastin microfibrillar interface proteins (EMILINs) and Multimerins (EMILIN1, EMILIN2, Uday Kishore, Brunel University, UK Multimerin1, and Multimerin2) constitute a four member family that in addition to the Reviewed by: shared C-terminus gC1q domain typical of the gC1q/TNF superfamily members contain a Uday Kishore, Brunel University, UK Kenneth Reid, Green Templeton N-terminus unique cysteine-rich EMI domain. These glycoproteins are homotrimeric and College University of Oxford, UK assemble into high molecular weight multimers. They are predominantly expressed in *Correspondence: the extracellular matrix and contribute to several cellular functions in part associated with Alfonso Colombatti, Division of the gC1q domain and in part not yet assigned nor linked to other specific regions of the Experimental Oncology 2, Centro di sequence. Among the latter is the control of arterial blood pressure, the inhibition of Bacil- Riferimento Oncologico, Istituto di Ricerca e Cura a Carattere Scientifico, lus anthracis cell cytotoxicity, the promotion of cell death, the proangiogenic function, and 33081 Aviano, Italy.
    [Show full text]
  • Supplementary Table 1: Adhesion Genes Data Set
    Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like,
    [Show full text]
  • Multimerin-2 Is a Ligand for Group 14 Family C-Type Lectins CLEC14A, CD93 and CD248 Spanning the Endothelial Pericyte Interface
    OPEN Oncogene (2017) 36, 6097–6108 www.nature.com/onc ORIGINAL ARTICLE Multimerin-2 is a ligand for group 14 family C-type lectins CLEC14A, CD93 and CD248 spanning the endothelial pericyte interface KA Khan1, AJ Naylor2, A Khan1, PJ Noy1, M Mambretti1, P Lodhia1, J Athwal1, A Korzystka1, CD Buckley2, BE Willcox3, F Mohammed3 and R Bicknell1 TheC-typelectindomaincontaininggroup14familymembers CLEC14A and CD93 are proteins expressed by endothelium and are implicated in tumour angiogenesis. CD248 (alternatively known as endosialin or tumour endothelial marker-1) is also a member of this family and is expressed by tumour-associated fibroblasts and pericytes. Multimerin-2 (MMRN2) is a unique endothelial specific extracellular matrix protein that has been implicated in angiogenesis and tumour progression. We show that the group 14 C-type lectins CLEC14A, CD93 and CD248 directly bind to MMRN2 and only thrombomodulin of the family does not. Binding to MMRN2 is dependent on a predicted long-loop region in the C-type lectin domainandisabrogatedbymutationwithinthedomain. CLEC14A and CD93 bind to the same non-glycosylated coiled-coil region of MMRN2, but the binding of CD248 occurs on a distinct non-competing region. CLEC14A and CD248 can bind MMRN2 simultaneously and this occurs at the interface between endothelium and pericytes in human pancreatic cancer. A recombinant peptide of MMRN2 spanning the CLEC14A and CD93 binding region blocks CLEC14A extracellular domain binding to the endothelial cellsurfaceaswellasincreasingadherenceofhumanumbilical vein endothelial cells to the active peptide. This MMRN2 peptide is anti-angiogenic in vitro and reduces tumour growth in mouse models. These findings identify novel protein interactions involving CLEC14A, CD93 and CD248 with MMRN2 as targetable components of vessel formation.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • RAP2 Mediates Mechanoresponses of the Hippo Pathway Zhipeng Meng1, Yunjiang Qiu2,3, Kimberly C
    LETTER https://doi.org/10.1038/s41586-018-0444-0 RAP2 mediates mechanoresponses of the Hippo pathway Zhipeng Meng1, Yunjiang Qiu2,3, Kimberly C. Lin1, Aditya Kumar4, Jesse K. Placone4, Cao Fang1, Kuei-Chun Wang4,5, Shicong Lu1, Margaret Pan1, Audrey W. Hong1, Toshiro Moroishi1,6,7, Min Luo1,8, Steven W. Plouffe1, Yarui Diao2, Zhen Ye2, Hyun Woo Park1,9, Xiaoqiong Wang10, Fa-Xing Yu11, Shu Chien4,5, Cun-Yu Wang12, Bing Ren2,13, Adam J. Engler4 & Kun-Liang Guan1* Mammalian cells are surrounded by neighbouring cells and Extended Data Fig. 1b). Expression of the YAP and TAZ target extracellular matrix (ECM), which provide cells with structural genes CTGF, CYR61, and ANKRD1 was repressed by low stiffness in support and mechanical cues that influence diverse biological wild-type cells, but not in RAP2-KO cells (Fig. 1f). Similar results were processes1. The Hippo pathway effectors YAP (also known as YAP1) observed in human mesenchymal stem cells (Extended Data Fig. 1c–e), and TAZ (also known as WWTR1) are regulated by mechanical in which RAP2 deletion suppressed differentiation into adipocytes cues and mediate cellular responses to ECM stiffness2,3. Here we (Extended Data Fig. 1f, g). In luminal breast cancer MCF7 cells, identified the Ras-related GTPase RAP2 as a key intracellular ECM stiffness modulated localization of YAP and TAZ in a RAP2- signal transducer that relays ECM rigidity signals to control dependent manner, whereas the basal type MDA-MB-468 cells showed mechanosensitive cellular activities through YAP and TAZ. constitutively cytoplasmic localization of YAP and TAZ regardless RAP2 is activated by low ECM stiffness, and deletion of RAP2 of stiffness (Extended Data Fig.
    [Show full text]
  • SHOC2–MRAS–PP1 Complex Positively Regulates RAF Activity and Contributes to Noonan Syndrome Pathogenesis
    SHOC2–MRAS–PP1 complex positively regulates RAF activity and contributes to Noonan syndrome pathogenesis Lucy C. Younga,1, Nicole Hartiga,2, Isabel Boned del Ríoa, Sibel Saria, Benjamin Ringham-Terrya, Joshua R. Wainwrighta, Greg G. Jonesa, Frank McCormickb,3, and Pablo Rodriguez-Vicianaa,3 aUniversity College London Cancer Institute, University College London, London WC1E 6DD, United Kingdom; and bHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94158 Contributed by Frank McCormick, September 18, 2018 (sent for review November 22, 2017; reviewed by Deborah K. Morrison and Marc Therrien) Dephosphorylation of the inhibitory “S259” site on RAF kinases CRAF/RAF1 mutations are also frequently found in NS and (S259 on CRAF, S365 on BRAF) plays a key role in RAF activation. cluster around the S259 14-3-3 binding site, enhancing CRAF ac- The MRAS GTPase, a close relative of RAS oncoproteins, interacts tivity through disruption of 14-3-3 binding (8) and highlighting the with SHOC2 and protein phosphatase 1 (PP1) to form a heterotri- key role of this regulatory step in RAF–ERK pathway activation. meric holoenzyme that dephosphorylates this S259 RAF site. MRAS is a very close relative of the classical RAS oncoproteins MRAS and SHOC2 function as PP1 regulatory subunits providing (H-, N-, and KRAS, hereafter referred to collectively as “RAS”) the complex with striking specificity against RAF. MRAS also func- and shares most regulatory and effector interactions as well as tions as a targeting subunit as membrane localization is required transforming ability (9–11). However, MRAS also has specific for efficient RAF dephosphorylation and ERK pathway regulation functions of its own, and uniquely among RAS family GTPases, it in cells.
    [Show full text]
  • EGFL7 Meets Mirna-126: an Angiogenesis Alliance
    - http://vascularcell.com/ REVIEW | OPEN ACCESS EGFL7 meets miRNA-126: an angiogenesis alliance Journal of Angiogenesis Research 2:9 | DOI: 10.1186/2040-2384-2-9 | © Li et al.; licensee Publiverse Online S.R.L. 2010 Received: 21 Apr 2010 | Accepted: 8 Apr 2010 | Published: 8 Apr 2010 Nikolic Iva, Plate Karl-Heinz, Schmidt Mirko HH@ + Contributed equally@ Corresponding author Abstract Blood vessels form de novo through the tightly regulated programs of vasculogenesis and angiogenesis. Both processes are distinct but one of the steps they share is the formation of a central lumen, when groups of cells organized as vascular cords undergo complex changes to achieve a tube-like morphology. Recently, a protein termed epidermal growth factor-like domain 7 (EGFL7) was described as a novel endothelial cell-derived factor involved in the regulation of the spatial arrangement of cells during vascular tube assembly. With its impact on tubulogenesis and vessel shape EGFL7 joined the large family of molecules governing blood vessel formation. Only recently, the molecular mechanisms underlying EGFL7's effects have been started to be elucidated and shaping of the extracellular matrix (ECM) as well as Notch signaling might very well play a role in mediating its biological effects. Further, findings in knock-out animal models suggest miR-126, a miRNA located within the egfl7 gene, has a major role in vessel development by promoting VEGF signaling, angiogenesis and vascular integrity. This review summarizes our current knowledge on EGFL7 and miR-126 and we will discuss the implications of both bioactive molecules for the formation of blood vessels.
    [Show full text]
  • The RAS–Effector Interaction As a Drug Target Adam B
    Published OnlineFirst January 6, 2017; DOI: 10.1158/0008-5472.CAN-16-0938 Cancer Review Research The RAS–Effector Interaction as a Drug Target Adam B. Keeton1,2, E. Alan Salter3, and Gary A. Piazza1,2 Abstract About a third of all human cancers harbor mutations in one direct inhibitors of RAS proteins. Here, we review this evidence of the K-, N-, or HRAS genes that encode an abnormal RAS with a focus on compounds capable of inhibiting the interac- protein locked in a constitutively activated state to drive malig- tion of RAS proteins with their effectors that transduce the nant transformation and tumor growth. Despite more than signals of RAS and that drive and sustain malignant transfor- three decades of intensive research aimed at the discovery of mation and tumor growth. These reports of direct-acting RAS RAS-directed therapeutics, there are no FDA-approved drugs inhibitors provide valuable insight for further discovery and that are broadly effective against RAS-driven cancers. Although development of clinical candidates for RAS-driven cancers RAS proteins are often said to be "undruggable," there is involving mutations in RAS genes or otherwise activated RAS mounting evidence suggesting it may be feasible to develop proteins. Cancer Res; 77(2); 221–6. Ó2017 AACR. Introduction Activating mutations at codons 12, 13, or 61 of KRAS occur de novo in approximately one third of all human cancers and are Cancer is a leading cause of death in the developed world with especially prevalent in pancreatic, colorectal, and lung tumors. more than one million people diagnosed and more than 500,000 These mutations affect the P-loop and switch-2 regions of the deaths per year in the United States alone.
    [Show full text]
  • Differences in Gene Expression Profiles and Carcinogenesis Pathways Involved in Cisplatin Resistance of Four Types of Cancer
    596 ONCOLOGY REPORTS 30: 596-614, 2013 Differences in gene expression profiles and carcinogenesis pathways involved in cisplatin resistance of four types of cancer YONG YANG1,2, HUI LI1,2, SHENGCAI HOU1,2, BIN HU1,2, JIE LIU1,3 and JUN WANG1,3 1Beijing Key Laboratory of Respiratory and Pulmonary Circulation, Capital Medical University, Beijing 100069; 2Department of Thoracic Surgery, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020; 3Department of Physiology, Capital Medical University, Beijing 100069, P.R. China Received December 23, 2012; Accepted March 4, 2013 DOI: 10.3892/or.2013.2514 Abstract. Cisplatin-based chemotherapy is the standard Introduction therapy used for the treatment of several types of cancer. However, its efficacy is largely limited by the acquired drug Cisplatin is primarily effective through DNA damage and is resistance. To date, little is known about the RNA expression widely used for the treatment of several types of cancer, such changes in cisplatin-resistant cancers. Identification of the as testicular, lung and ovarian cancer. However, the ability RNAs related to cisplatin resistance may provide specific of cancer cells to become resistant to cisplatin remains a insight into cancer therapy. In the present study, expression significant impediment to successful chemotherapy. Although profiling of 7 cancer cell lines was performed using oligo- previous studies have identified numerous mechanisms in nucleotide microarray analysis data obtained from the GEO cisplatin resistance, it remains a major problem that severely database. Bioinformatic analyses such as the Gene Ontology limits the usefulness of this chemotherapeutic agent. Therefore, (GO) and KEGG pathway were used to identify genes and it is crucial to examine more elaborate mechanisms of cisplatin pathways specifically associated with cisplatin resistance.
    [Show full text]
  • Structure-Based Development of New RAS-Effector Inhibitors from a Combination of Active and Inactive RAS-Binding Compounds
    Structure-based development of new RAS-effector inhibitors from a combination of active and inactive RAS-binding compounds Abimael Cruz-Migonia,b,1, Peter Canninga,1,2, Camilo E. Quevedoa,1, Carole J. R. Bataillec, Nicolas Berya, Ami Millera, Angela J. Russellc, Simon E. V. Phillipsb,d, Stephen B. Carrb,d, and Terence H. Rabbittsa,3 aWeatherall Institute of Molecular Medicine, MRC Molecular Haematology Unit, John Radcliffe Hospital, University of Oxford, OX3 9DS Oxford, United Kingdom; bResearch Complex at Harwell, Rutherford Appleton Laboratory, OX11 0FA Didcot, United Kingdom; cChemistry Research Laboratory, University of Oxford, OX1 3TA Oxford, United Kingdom; and dDepartment of Biochemistry, University of Oxford, OX1 3QU Oxford, United Kingdom Edited by James A. Wells, University of California, San Francisco, CA, and approved December 17, 2018 (received for review July 6, 2018) The RAS gene family is frequently mutated in human cancers, and transferase inhibitors also proved to be ineffective, failing to the quest for compounds that bind to mutant RAS remains a major demonstrate antitumor activity in KRAS-driven cancers (12). As goal, as it also does for inhibitors of protein–protein interactions. an alternative to compounds, various macromolecules [called Q61H We have refined crystallization conditions for KRAS169 -yield- macrodrugs (13)] have been developed that can bind to RAS and ing crystals suitable for soaking with compounds and exploited prevent PPI with the RAS effectors, such as has been shown with this to assess new RAS-binding compounds selected by screening intracellular antibody fragments (14, 15). The possible clinical a protein–protein interaction-focused compound library using sur- use of these macrodrugs has not been implemented thus far due face plasmon resonance.
    [Show full text]
  • WO 2013/184908 A2 12 December 2013 (12.12.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2013/184908 A2 12 December 2013 (12.12.2013) P O P C T (51) International Patent Classification: Jr.; One Procter & Gamble Plaza, Cincinnati, Ohio 45202 G06F 19/00 (201 1.01) (US). HOWARD, Brian, Wilson; One Procter & Gamble Plaza, Cincinnati, Ohio 45202 (US). (21) International Application Number: PCT/US20 13/044497 (74) Agents: GUFFEY, Timothy, B. et al; c/o The Procter & Gamble Company, Global Patent Services, 299 East 6th (22) Date: International Filing Street, Sycamore Building, 4th Floor, Cincinnati, Ohio 6 June 2013 (06.06.2013) 45202 (US). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (30) Priority Data: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, 61/656,218 6 June 2012 (06.06.2012) US DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (71) Applicant: THE PROCTER & GAMBLE COMPANY HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, [US/US]; One Procter & Gamble Plaza, Cincinnati, Ohio KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, 45202 (US). MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, (72) Inventors: XU, Jun; One Procter & Gamble Plaza, Cincin SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, nati, Ohio 45202 (US).
    [Show full text]